UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ ...

Exhibit 99.1 Final AUGUST 12, 2024 IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (August 14, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immuno-oncology therapy, today reported financial results for the three and six months ended June 30, 2024. The Company also provided an update on its clinical development programs with IMNN-001, ...

LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and nextgeneration vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 ...

Core Viewpoint - IMUNON, Inc. is set to host a conference call on August 14, 2024, to discuss its Q2 2024 financial results and provide updates on its clinical development programs, particularly focusing on IMNN-001 for ovarian cancer and its PlaCCine modality for next-generation vaccines [1]. Group 1: Company Overview - IMUNON is a clinical-stage biotechnology company that develops DNA-mediated immunotherapy and next-generation vaccines, utilizing non-viral DNA technology [4]. - The company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy currently in Phase 2 development for advanced ovarian cancer, designed to produce cancer-fighting molecules at the tumor site [5]. Group 2: Clinical Development Programs - IMNN-001 targets first-line, locally advanced-stage ovarian cancer and aims to instruct the body to generate durable levels of IL-12 and interferon gamma at the tumor site [5]. - The PlaCCine modality is a proprietary DNA plasmid technology aimed at delivering viral antigens to elicit strong immunological responses for vaccine development [1][4]. Group 3: Conference Call Details - The conference call will take place at 11:00 a.m. ET on August 14, 2024, with participation options available via toll-free and international dialing [2]. - An archived replay of the call will be accessible until August 28, 2024, with specific access codes provided for listeners [3].

LAWRENCEVILLE, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at-the-market under Nasdaq rules. In a concurrent private placement and also pursuant to the securities purchase agreements, the Company has agreed to issue to the investors unregistered warrants to ...

IMUNON Inc IMNN stock is surging on Tuesday, with a strong session volume of 117.8 million as per data from Benzinga Pro. OVATION 2 is a randomized study of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (NACT) inclusive of interval debulking or cytoreductive surgery compared with a control arm of standard-ofcare NACT alone. Highlights from patients treated with IMNN-001 plus standard-of-care in a first-line treatment setting include: The PFS results, the trial's primary endpoint, suppor ...

Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-totreat patient population compared with the standard-of-care control arm OS was extended by 15.7 months in patients receiving three or more doses of IMNN-001 in the 17- dose protocol Patients also receiving maintenance PARP inhibitor therapy demonstrated an OS hazard ratio of 0.41 in the IMNN-001 trial arm with median OS not y ...

Core Insights - IMUNON, Inc. announced positive topline results from the Phase 2 OVATION 2 Study of IMNN-001, demonstrating a significant improvement in overall survival (OS) for patients with advanced ovarian cancer compared to standard-of-care treatment [1][3][8] - The study showed a hazard ratio of 0.74 in the intent-to-treat population, indicating a 35% improvement in survival, with a median OS increase of 11.1 months [7][19] - IMUNON plans to initiate a registrational study in Q1 2025 and is preparing for an End-of-Phase 2 meeting with the U.S. FDA [1][10] Study Design and Results - The OVATION 2 Study was a randomized trial evaluating the safety and efficacy of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer [2][12] - A total of 112 patients were enrolled and randomized 1:1 to receive either IMNN-001 plus standard-of-care chemotherapy or standard-of-care alone [2] - The primary endpoint of progression-free survival (PFS) showed a three-month improvement for the IMNN-001 treatment arm, with a hazard ratio of 0.79, indicating a 27% improvement in delaying progression [17] Clinical Significance - The results indicate that the addition of IMNN-001 could extend median OS from 29 months with standard treatment to 40 months, which is considered clinically meaningful [3][19] - Among patients receiving three or more doses of IMNN-001, there was a further increase in median OS by 15.7 months, with a hazard ratio of 0.64, representing a 56% improvement in survival [7][9] - For patients treated with a PARP inhibitor, the hazard ratio decreased to 0.41, with median OS not yet reached in the IMNN-001 arm compared to 37.1 months in the control arm [7][19] Future Directions - IMUNON aims to advance IMNN-001 into a Phase 3 pivotal study as soon as possible, with plans to present full study results at an upcoming medical conference [8][10] - The company is focused on addressing the unmet medical needs of over 300,000 women diagnosed with advanced ovarian cancer annually [8][12]

Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will issue a news release announcing topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer tomorrow, July 30, at approximately 8:00 a.m. Eastern time, and will host an investment community ...

Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time To participate in the conference call, please dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON call. A live webcast of the call will be available here. About IMUNON LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will issue a news ...